Published in Medical Letter on the CDC and FDA, December 17th, 2006
The study, whose primary purpose is to evaluate the safety of Celaderm in humans, is expected to enroll 55 patients at six clinical sites in the United States and will also assess the potential for Celaderm to accelerate healing of venous leg ulcers.
"We are delighted to begin working with some of the world's leading investigators on the clinical development of this exciting new product," said David Eisenbud,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.